News AZ grabs pair of EU approvals for top cancer drugs AstraZeneca is celebrating two approvals for cancer drugs Imfinzi and Enhertu in the EU as it faces increased competition to its top-seller Tagrisso.
News ACC25: AZ stakes its claim to the oral PCSK9 category AstraZeneca reveals phase 2b results with its oral PCSK9 inhibitor AZD0780 as it tries to narrow a lead held by MSD with its rival cholesterol drug.
News ACC25: Mineralys' uncontrolled hypertension drug aces trial Mineralys looks odds on to become the first drug developer to bring an aldosterone synthase inhibitor to market for uncontrolled hypertension.
News J&J throws the gauntlet down to AZ with new survival data New survival data from MARIPOSA for Johnson & Johnson's Rybrevant/Lazcluze combination in lung cancer could spell trouble for AstraZeneca.
News AZ builds in China, as J&J ramps up its US investments AstraZeneca will open its sixth R&D centre in China, while J&J announces four new manufacturing facilities in the US in a major reshoring drive.
News AstraZeneca buys cell therapy biotech for up to $1bn AstraZeneca plans to acquire Belgian in vivo cell therapy biotech EsoBiotec and has signed a pair of licensing deals with drug delivery firm Alteogen.
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.